Two New York state companies have been chosen to participate this spring in the Cornell Center for Materials Research JumpStart Program, through which they will collaborate with faculty members to develop and improve their products.
A type of cell widely used for brain research and drug development may have been leading researchers astray for years, according to a study from scientists at Weill Cornell Medicine and Columbia University.
Poor function of the gene SMC3 can lead to improper immune cell development, and to cancer, by disrupting how DNA is structured inside the cell nucleus, according to new research from Weill Cornell Medicine.
As CCSS fellows, a dozen faculty members representing seven colleges and schools will pursue ambitious research projects on issues ranging from political polarization to environmental justice.
Cases of symptomatic COVID-19 were extremely low among children and staff at a network of North Carolina YMCA day camps that took precautions like masking and physical distancing, researchers have found.
Elucida Oncology, a biotechnology company based on C Dots – ultra-small nanoparticles developed at Cornell that show promise in identifying and fighting cancer – recently secured $44 million in financing.
Researchers devised a new method of using extracts to create shelf-stable vaccines on demand, a potentially game-changing approach to fighting infection in regions that have limited access to such medicines.
A $2.65 million gift to support Cornell and partner research in Tanzania will improve distribution of new and more resistant varieties of cassava while empowering women and marginalized groups in the East African nation.
Cornell Engineering startup Organic Robotics Corporation and its stretchable sensing technology, Light Lace, topped a field of four finalists to win the sixth annual NFL 1st & Future competition, sponsored by the National Football League.
